Effects of age on antiretroviral plasma drug concentration in hivinfected subjects undergoing routine therapeutic drug monitoring

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 6, 2013, Pages 1354-1359

  Winston, Alan ^a,b   Jose, Sophie ^c   Gibbons, Sara ^d   Back, David ^d   Stohr, Wolfgang ^e   Post, Frank ^f   Fisher, Martin ^g   Gazzard, Brian ^h   Nelson, Mark ^h   Gilson, Richard ^c   Orkin, Chloe ⁱ   Johnson, Margaret ^j   Palfreeman, Adrian ^k   Chadwick, David ^l   Leen, Clifford ^m   Schwenk, Achim ⁿ   Anderson, Jane ^o   Gompels, Mark ^p   Dunn, David ^e   Khoo, Saye ^d   Sabin, Caroline ^c   more..

^a ST MARY S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e MRC CLINICAL TRIALS UNIT   (United Kingdom)

^f KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^g UK   (United Kingdom)

^h CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

ⁱ ROYAL LONDON HOSPITAL   (United Kingdom)

^j ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^k UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^l SOUTH TEES HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^m UNIVERSITY OF EDINBURGH   (United Kingdom)

ⁿ NORTH MIDDLESEX UNIVERSITY HOSPITAL NHS TRUST   (United Kingdom)

^o HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^p NORTH BRISTOL NHS TRUST   (United Kingdom)

more..

Author keywords

Ageing; Antiretroviral therapy; Cohort; Pharmacokinetics; TDM

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; EFAVIRENZ; LOPINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADOLESCENT; ADULT; AGED; AGING; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANALYSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ASSESSMENT; COHORT ANALYSIS; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; TIME TO TREATMENT;

AGEING; ANTIRETROVIRAL THERAPY; COHORT; PHARMACOKINETICS; TDM;

ADULT; AGED; AGING; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COHORT STUDIES; DRUG MONITORING; FEMALE; GREAT BRITAIN; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER FUNCTION TESTS; MALE; MASS SPECTROMETRY; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 84883244574     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt029     Document Type: Article

References (21)

1. Bhaskaran K, Hamouda O, Sannes M et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300: 51-9.
2. Negin J, Cumming RG. HIV infection in older adults in sub-Saharan Africa: extrapolating prevalence from existing data. Bull World Health Organ 2012; 88: 847-53.
3. Evans MA, Triggs EJ, Cheung M et al. Gastric emptying rate in the elderly: implications for drug therapy. J Am Geriatr Soc 1981; 29: 201-5.
4. Lamy PP. Comparative pharmacokinetic changes and drug therapy in an older population. J Am Geriatr Soc 1982; 30 Suppl: S11-9.
5. Castleden CM, George CF. The effect of ageing on the hepatic clearance of propranolol. Br J Clin Pharmacol 1979; 7: 49-54.
6. Aymanns C, Keller F, Maus S et al. Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clin J Am Soc Nephrol 2010; 5: 314-27.
7. Lee HC, Huang KTL, Shen WK. Use of antiarrhythmic drugs in elderly patients. J Geriatr Cardiol 2011; 8: 184-94.
8. Marzolini C, Elzi L, Gibbons S et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther 2010; 15: 413-23.
9. Garvey L, Latch N, Erlwein OWet al. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients. Antivir Ther 2010; 15: 213-8.
10. Dumond JB, Adams JL, Prince HMA et al. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study. In: Abstracts of the Second International Workshop on HIV and Ageing, Baltimore, MA, 2011. Abstract O_12.
11. Sabin CA, Smith CJ, Delpech V et al. The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy. HIV Med 2009; 10: 35-43.
12. Silverberg MJ, Leyden W, Horberg MA et al. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med 2007; 167: 684-91.
13. The UK Collaborative HIV Cohort Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004; 5: 115-24.
14. Stohr W, Back D, Dunn D et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther 2008; 13: 675-85.
15. Dickinson L, Robinson L, Tjia J et al. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 829: 82-90.
16. Else L, Watson V, Tjia J et al. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 1455-65.
17. Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med 2007; 4: 106-19.
18. Dong BJ, Zheng Y, Hughes MD et al. Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS 2012; 26: 833-41.
19. Riska P, Lamson M, MacGregor T et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 1999; 27: 895-901.
20. Williams I, Churchill D, Anderson J et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012; 13 Suppl 2: 1-6.
21. Jourdan M, Vaubourdolle M, Cynober L et al. Effect of aging on liver functions-an experimental study in a perfused rat liver model. Exp Gerontol 2004; 39: 1341-6.